Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[S,S]-Reboxetine in Chronic Painful Diabetic Peripheral Neuropathy
NCT00348894Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jul 2006
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial of esreboxetine in diabetic peripheral neuropathy (DPN) (2 arms), sponsored by Pfizer. Primary endpoints: Vital signs, Physical examination and 3 more. Started Jul 2006; status: terminated.
02
Drugs
esreboxetine
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT00348894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00348894.